MedDataX Logo

GRK4 Polymorphisms Blood Pressure Response to Candesartan

NCT ID: NCT01629225

Last Updated: 2014-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Essential Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

candesartan

All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.

Group Type NO_INTERVENTION

Candesartan

Intervention Type DRUG

To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Candesartan

To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GRK4 polymorphisms and essential hypertrension

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* men and women with mild to moderate essential hypertension in southwestern Han Chinese

Exclusion Criteria

* subjects unwilling to participate or subjects did not have all measurement required,
* subjects who were on medications, which affect blood pressure or
* whose DNA failed to amplify and 8 with errors in Mendelian segregation
Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Third Military Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yu Changqing

Department of Cardiovascular Diseases; Institute of Cardiovascular Diseases; Daping Hospital;

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zeng Chunyu, Doctor

Role: STUDY_DIRECTOR

TMMU

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Cardiology, Daping Hospital, The Third Military Medical University

Chongqing, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yu changqing, Doctor

Role: CONTACT

[email protected]
02368731850

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yu Changqing, MD

Role: primary

[email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Cai Y, Yang Y, Chen X, He D, Zhang X, Wen X, Hu J, Fu C, Qiu D, Jose PA, Zeng C, Zhou L. Circulating "LncPPARdelta" From Monocytes as a Novel Biomarker for Coronary Artery Diseases. Medicine (Baltimore). 2016 Feb;95(6):e2360. doi: 10.1097/MD.0000000000002360.

Reference Type DERIVED
PMID: 26871769 (View on PubMed)

Yang Y, Cai Y, Wu G, Chen X, Liu Y, Wang X, Yu J, Li C, Chen X, Jose PA, Zhou L, Zeng C. Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease. Clin Sci (Lond). 2015 Oct 1;129(8):675-85. doi: 10.1042/CS20150121. Epub 2015 Jun 11.

Reference Type DERIVED
PMID: 26201019 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ThirdMMU

Identifier Type: -

Identifier Source: org_study_id